ImmunityBio has surged over 200% YTD, yet I see little fundamental justification for its current $10B enterprise value. ANKTIVA’s Q4 revenue ramped to $38.3M, but high cash burn and speculative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results